OmniAb (OABI) Preferred Stock Liabilities (2021 - 2022)
OmniAb (OABI) posted quarterly Preferred Stock Liabilities of $237.2 million for Q3 2022, up 0.61% year-over-year from $235.8 million in Q3 2021, and little changed quarter-over-quarter from $236.1 million in Q2 2022.
OmniAb (OABI) Preferred Stock Liabilities (2021 - 2022) Analysis & Trends
OmniAb (OABI) has reported Preferred Stock Liabilities for 2 consecutive years, with $237.2 million the latest figure, recorded in Q3 2022.
- In Q3 2022, Preferred Stock Liabilities rose 0.61% year-over-year to $237.2 million; the TTM figure through Sep 2022 stood at $237.2 million (up 0.61% YoY), while the FY2021 annual figure was $235.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities was little changed at $237.2 million in Q3 2022 per OABI's latest filing, from $236.1 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $237.2 million in Q3 2022 and bottomed at $235.8 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 237.19 Mn |
| Jun 30, 2022 | 236.10 Mn |
| Mar 31, 2022 | 235.75 Mn |
| Dec 31, 2021 | 235.75 Mn |
| Sep 30, 2021 | 235.75 Mn |